SOD1 and amyotrophic lateral sclerosis: This finding suggests that pharmacological modulation of MAMs could be beneficial to motoneurons also in models that are not related to mutated SOD1 pathology, and opens therapeutic perspectives for ALS/HMSN diseases involving MAM dysfunction.